The global neglected tropical disease treatment market is anticipated to expand at a substantial CAGR during forecast period, between 2020 and 2027. Neglected tropical diseases are commonly seen in the areas where people do not have access to clean water or safe ways to dispose human waste.
Request Free Sample Report Here
Neglected tropical disease (NTD) refers to a heterogeneous and diverse group of communicable diseases that prevail in the subtropical and tropical conditions in around 149 countries. These diseases are caused by pathogens such as bacteria, protozoa, viruses, and helminthes. NTDs can be prevented by controlling the vectors transmitting diseases such as black flies and mosquitoes and by maintaining sanitation & hygiene. NTDs are concentrated in settings of extreme poverty in urban slums, remote rural areas, and conflict zones in Africa, Latin America, and Asia.
Market Trends, Drivers, Restraints, and Opportunities:
- Rising government initiatives against NTDs is expected to boost the market during the forecast period.
- Growing burden of NTDs in tropical and subtropical countries globally is propelling the market growth.
- Low healthcare budget and limited operating revenue opportunities for research & development of targeted therapies are anticipated to impede the neglected tropical disease treatment market in the coming years.
- High demand for disease specific novel treatments is providing opportunities in the market.
Neglected Tropical Disease Treatment Market Segment Insights:
Rising R&D activities for Chagas disease treatment drives segment growth
In terms of disease types, the global neglected tropical disease treatment market can be categorized as Mediterranean fever, Ebola virus infection, Chagas disease, Zika virus infection, Chikungunya, and others. The Chagas disease segment held a substantial share of the market share in 2019 and is anticipated to expand at a moderate CAGR during the forecast period due to factors such as rising research activities for the development of Chagas disease treatments and growing occurrence of the disease owing to unhygienic conditions. Moreover, approvals for novel products used to treat the disease are expected to propel segmental growth in the near future.
Presence of pipeline products to propel segmental growth
Based on treatment types, the market can be bifurcated into drugs and vaccine. The drugs segment is sub-divided into analgesics, antipyretics, antibiotics, and others. The vaccine segment is sub-segmented into dengvaxia, mosquirix, and others. The vaccines segment is anticipated to expand at a high CAGR during the forecast period owing to the presence of pipeline products and increasing focus of market players to develop vaccines for NTDs.
Awareness about the advantages of oral route of administration boosts segment growth
On the basis of routes of administration, the global neglected tropical disease treatment market can be classified as oral and injectable. The oral segment dominated the market in 2019 and is projected to expand at a high CAGR during the forecast period due patient compliance, ease of ingestion, pain avoidance, safety, and versatility to accommodate various types of drugs.
Access to a large patient pool in hospitals propels the segment
In terms of end-users, the market can be divided into hospitals, homecare, specialty clinics, and others. The hospitals segment is anticipated to expand at a substantial CAGR during the forecast period due to the availability of superior medical treatments for NTDs in hospitals. Moreover, hospitals provide cater to large patient pool.
Retail pharmacies segment accounts for a dominant share of the market
On the basis of distribution channels, the market can be segmented into hospital pharmacies, retail pharmacies, and others. Retail pharmacies segment is projected to be a lucrative segment of the market during the forecast period. In retail pharmacies, pharmacists interact with the patients to provide targeted counseling. This results in a better experience for the customer, hence most people tend to purchase their medications from retail pharmacy.
Asia Pacific is expected to account for a significant share of the global market
Based on regions, the global neglected tropical disease treatment market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Asia Pacific is expected to account for a large share of the market owing to factors such as continuously increasing GDP, presence of a large target population, and high prevalence of neglected tropical diseases in this region.
Competitive Analysis
Key players in the global neglected tropical disease treatment market includes Emergent BioSolutionsInc, Moderna, Valneva SE, Johnson & Johnson Services, Inc, DAIICHI SANKYO COMPANY, LIMITED, InsudPharma group, Humanigen, Inc, Savant HWP, Inc, Bayer AG, Eisai Co., Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Themis Bioscience GmbH, Novartis AG, and Amneal Pharmaceuticals LLC. Collaborations, mergers, acquisitions, agreements, and partnerships are strategies adopted by these players to strengthen their geographical presence.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.Report Scope:The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development.
Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.Request a Report Sample with Toc and figures to click here: http://marketgrowthanalysis.com/reports/sample/450Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships.
These cover all the WHO participating countries which are described in detail in the subsequent section.Report Includes:- An overview of the global markets for tropical disease treatments.- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.- A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.- Representations of market shares by geography, company, and future outlook.- Insight on some of the newer drug candidates, clinical trials, and their end points.- Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.- Profiles of major players in the industry.Request for enquiry on This Report at: http://marketgrowthanalysis.com/reports/enquiry/450Report SummaryNeglected tropical diseases are a significant cause of death and morbidity among affected communities around the world.
The global market for malaria treatments in 2015 was about $440.3 million (including preventive medicine for pregnant women and children under five years of age in Africa) and is expectedto reach $757.9 million by 2021.
Our projection of the market for Lymphatic Filariasis, for the year 2021, comes to $8,500.
This falls in line with WHO’s roadmap in which the global market for preventivechemotherapy will be reduced to near negligible with a very limited market for drugs.
The global Neglected Tropical Diseases Diagnosis Market report published by Reports and Data is an investigative report providing a comprehensive study of the global Neglected Tropical Diseases Diagnosis market with regards to market share, market size, market analysis, industry revenue, current and emerging trends, and latest technological developments.
The report highlights the competitive landscape of the Neglected Tropical Diseases Diagnosis market with focus on company overview, business expansion plans, analysis of top companies, annual sales, and other market projections.
It offers a comprehensive analysis of the competitive landscape of the Neglected Tropical Diseases Diagnosis market along with key collaborations and partnerships between key players of the market.
The report investigates key aspects such as financial standing, research and development, product offerings, current deals, investments, and strategic alliances such as mergers and acquisitions, joint ventures, product launches, brand promotions, and corporate deals, among others.Key market players analyzed in the report are:Thermo Fisher Scientific Inc, ZeptoMetrix Inc, InBios International Inc, Abbott, Genome Diagnostics Pvt.
Ltd, Coris Bioconcept SPRL, Omega Diagnostics Group PLC, DiaSys Diagnostic Systems GmbH, and Oscar Medicare Pvt.
Ltd.Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/4059The report further segments the Neglected Tropical Diseases Diagnosis market on the basis of key product types, end-users, and applications.
